These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 18058448)

  • 1. Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol.
    Brand BA; de Boer JN; Oude Ophuis SBJ; Slot MIE; De Wilde B; Catthoor KCEER; Goverde AJ; Bakker PR; Marcelis MC; Grootens KP; Luykx JJ; Heringa SM; Weickert CS; Sommer IEC; Weickert TW
    Contemp Clin Trials Commun; 2020 Dec; 20():100681. PubMed ID: 33364517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder.
    Bagdadi N; N Azab A; Shvartsur R
    Psychiatry Clin Psychopharmacol; 2021 Sep; 31(3):344-352. PubMed ID: 38765942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis.
    de Boer J; Prikken M; Lei WU; Begemann M; Sommer I
    NPJ Schizophr; 2018 Jan; 4(1):1. PubMed ID: 29321530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The UNC-Wisconsin Rhesus Macaque Neurodevelopment Database: A Structural MRI and DTI Database of Early Postnatal Development.
    Young JT; Shi Y; Niethammer M; Grauer M; Coe CL; Lubach GR; Davis B; Budin F; Knickmeyer RC; Alexander AL; Styner MA
    Front Neurosci; 2017; 11():29. PubMed ID: 28210206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings.
    Gogos A; Sbisa AM; Sun J; Gibbons A; Udawela M; Dean B
    Int J Endocrinol; 2015; 2015():615356. PubMed ID: 26491441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.
    Kulkarni J; Gavrilidis E; Wang W; Worsley R; Fitzgerald PB; Gurvich C; Van Rheenen T; Berk M; Burger H
    Mol Psychiatry; 2015 Jun; 20(6):695-702. PubMed ID: 24732671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficits in latent inhibition induced by estradiol replacement are ameliorated by haloperidol treatment.
    Almey A; Hafez NM; Hantson A; Brake WG
    Front Behav Neurosci; 2013; 7():136. PubMed ID: 24101897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.
    Arad M; Weiner I
    Neuropsychopharmacology; 2010 Oct; 35(11):2179-92. PubMed ID: 20613719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?
    Arad M; Weiner I
    Neuropsychopharmacology; 2010 Jun; 35(7):1570-82. PubMed ID: 20237462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maturational trajectories of cortical brain development through the pubertal transition: unique species and sex differences in the monkey revealed through structural magnetic resonance imaging.
    Knickmeyer RC; Styner M; Short SJ; Lubach GR; Kang C; Hamer R; Coe CL; Gilmore JH
    Cereb Cortex; 2010 May; 20(5):1053-63. PubMed ID: 19703936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone.
    Arad M; Weiner I
    Psychopharmacology (Berl); 2009 Nov; 206(4):731-40. PubMed ID: 19169876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone modulation: a novel therapeutic approach for women with severe mental illness.
    Kulkarni J; Gurvich C; Gilbert H; Mehmedbegovic F; Mu L; Marston N; Gavrilidis E; de Castella A
    Aust N Z J Psychiatry; 2008 Jan; 42(1):83-8. PubMed ID: 18058448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen in severe mental illness: a potential new treatment approach.
    Kulkarni J; de Castella A; Fitzgerald PB; Gurvich CT; Bailey M; Bartholomeusz C; Burger H
    Arch Gen Psychiatry; 2008 Aug; 65(8):955-60. PubMed ID: 18678800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
    Kulkarni J; Gurvich C; Lee SJ; Gilbert H; Gavrilidis E; de Castella A; Berk M; Dodd S; Fitzgerald PB; Davis SR
    Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J; Huerta-Ramos E; Iniesta R; Cobo J; Araya S; Roca M; Serrano-Blanco A; Teba F; Ochoa S
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.